Katrien Wijndaele
Director, Health Outcomes, RWE Eli Lilly & Co.
Katrien Wijndaele, PhD, is an epidemiologist with over 20 years of experience leading RWE/observational research, developing cohort and interventional studies, analysing and disseminating primary and secondary data, and supervising epidemiologists in an international academic, public health and pharmaceutical context. In her current role at Eli Lilly, Katrien leads the cardio-metabolic health portfolio of RWE studies in the Nordics and the UK.
Seminars
Wednesday 25th February 2026
Target Trial Emulation: New Method or Rigorous Science?
11:00 am
- Introduce the target trial emulation framework and how it structures secondary data analyses using clearly defined study questions and design principles
- Explore the importance of clarity and transparency in real-world study design
- Discuss what a design-first approach means for industry when using secondary data, including implications for planning and execution of RWE studies
